Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in
treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in
which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature
blood cells) (chronic phase). Dasatinib, nilotinib, and imatinib mesylate may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth.